Modulation of T-Cell Mediated Immunity by Cytomegalovirus

  • Chris A. Benedict
  • Ramon Arens
  • Andrea Loewendorf
  • Edith M. Janssen


The herpesviruses have coevolved with their vertebrate hosts for over one hundred million years (McGeoch et al. 2000), resulting in a finely tuned equilibrium with the immune system. Consequently, all herpesviruses employ a multitude of strategies to modulate the host immune response, facilitating the establishment of lifelong latency and/or persistence in the face of a robust innate and adaptive immune response. Cytomegalovirus (CMV, a β-herpesvirus) is the largest of the herpesviruses, with a genome of ∼230 kB in size encoding >200 open reading frames (orfs). Approximately ∼60% of the encoded genes are not essential for replication of virus in tissue culture where there is no selective pressure from the host immune system and are predicted to perform immunomodulatory functions and facilitate establishment of latency (Murphy et al. 2003; Brocchieri et al. 2005). CMV directly targets dendritic cells (DC) and exploits the DC’s crucial role in the regulation of innate and adaptive anti-viral immune responses to promote replication and establish latency while preventing host pathology.


Dendritic Cell HCMV Infection Programme Death Ligand MCMV Infection Herpes Virus Entry Mediator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahn, K., A. Gruhler, et al. (1997). “The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP.” Immunity 6(5): 613–21.PubMedGoogle Scholar
  2. Andoniou, C. E., S. L. van Dommelen, et al. (2005). “Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity.” Nat Immunol 6(10): 1011–9.PubMedGoogle Scholar
  3. Andoniou, C. E., D. M. Andrews, et al. (2006). “Natural killer cells in viral infection: more than just killers.” Immunol Rev 214: 239–50.PubMedGoogle Scholar
  4. Andrews, D. M., C. E. Andoniou, et al. (2001). “Infection of dendritic cells by murine cytomegalovirus induces functional paralysis.” Nat Immunol 2(11): 1077–84.PubMedGoogle Scholar
  5. Andrews, D. M., C. E. Andoniou, et al. (2005). “Cross-talk between dendritic cells and natural killer cells in viral infection.” Mol Immunol 42(4): 547–55.PubMedGoogle Scholar
  6. Arens, R., P. Wang, et al. (2008). “Cutting edge: murine cytomegalovirus induces a polyfunctional CD4 T cell response.” J Immunol 180(10): 6472–6.PubMedGoogle Scholar
  7. Arens, R., A. Loewendorf, et al. (2011). Differential B7-CD28 costimulatory requirements for stable and inflationary MCMV-specific memory CD8 T cell populations. J Immunol 186, 3874–81.Google Scholar
  8. Arens, R., A. Loewendorf, et al. (2011). B7-mediated costimulation of CD4 T cells constrains cytomegalovirus persistence. J Virol 85, 390–6.PubMedGoogle Scholar
  9. Barber, D. L., E. J. Wherry, et al. (2006). “Restoring function in exhausted CD8 T cells during chronic viral infection.” Nature 439(7077): 682–7.PubMedGoogle Scholar
  10. Beck, K., U. Meyer-Konig, et al. (2003). “Human cytomegalovirus impairs dendritic cell function: a novel mechanism of human cytomegalovirus immune escape.” Eur J Immunol 33(6): 1528–38.PubMedGoogle Scholar
  11. Benedict, C. A., K. D. Butrovich, et al. (1999). “Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus.” J Immunol 162(12): 6967–70.PubMedGoogle Scholar
  12. Benedict, C. A., A. Loewendorf, et al. (2008). “Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway.” J Immunol 180(7): 4836–47.PubMedGoogle Scholar
  13. Biron, C. A., K. S. Byron, et al. (1989). “Severe herpesvirus infections in an adolescent without natural killer cells.” N Engl J Med 320(26): 1731–5.PubMedGoogle Scholar
  14. Blocki, F. A., S. Radhakrishnan, et al. (2006). “Induction of a gene expression program in dendritic cells with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC.” Faseb J 20(13): 2408–10.PubMedGoogle Scholar
  15. Boni, C., P. Fisicaro, et al. (2007). “Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.” J Virol 81(8): 4215–25.PubMedGoogle Scholar
  16. Brocchieri, L., T. N. Kledal, et al. (2005). “Predicting coding potential from genome sequence: application to betaherpesviruses infecting rats and mice.” J Virol 79(12): 7570–96.PubMedGoogle Scholar
  17. Bukowski, J. F., B. A. Woda, et al. (1984). “Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice.” J Virol 52(1): 119–28.PubMedGoogle Scholar
  18. Chang, W. L., N. Baumgarth, et al. (2004). “Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality.” J Virol 78(16): 8720–31.PubMedGoogle Scholar
  19. Cheng, J., Q. Ke, et al. (2009). “Cytomegalovirus infection causes an increase of arterial blood pressure.” PLoS Pathog 5(5): e1000427.PubMedGoogle Scholar
  20. Cheung, A. K., D. J. Gottlieb, et al. (2009). “The role of the human cytomegalovirus UL111A gene in downregulating CD4+ T cell recognition of latently infected cells: implications for virus elimination during latency.” Blood 114(19): 4128–37PubMedGoogle Scholar
  21. Cresswell, P., A. L. Ackerman, et al. (2005). “Mechanisms of MHC class I-restricted antigen processing and cross-presentation.” Immunol Rev 207: 145–57.PubMedGoogle Scholar
  22. Davison, A. J., A. Dolan, et al. (2003). “The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome.” J Gen Virol 84(Pt 1): 17–28.PubMedGoogle Scholar
  23. Dong, H., S. E. Strome, et al. (2002). “Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.” Nat Med 8(8): 793–800.PubMedGoogle Scholar
  24. French, A. R., J. T. Pingel, et al. (2004). “Escape of mutant double-stranded DNA virus from innate immune control.” Immunity 20(6): 747–56.PubMedGoogle Scholar
  25. Gaytant, M. A., E. A. Steegers, et al. (2002). “Congenital cytomegalovirus infection: review of the epidemiology and outcome.” Obstet Gynecol Surv 57(4): 245–56.PubMedGoogle Scholar
  26. Gold, M. C., M. W. Munks, et al. (2002). “The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo.” J Immunol 169(1): 359–65.PubMedGoogle Scholar
  27. Gold, M. C., M. W. Munks, et al. (2004). “Murine cytomegalovirus interference with antigen presentation has little effect on the size or the effector memory phenotype of the CD8 T cell response.” J Immunol 172(11): 6944–53.PubMedGoogle Scholar
  28. Greenberg, P. D. and S. R. Riddell (1999). “Deficient cellular immunity--finding and fixing the defects.” Science 285(5427): 546–51.PubMedGoogle Scholar
  29. Greenwald, R. J., G. J. Freeman, et al. (2005). “The B7 family revisited.” Annu Rev Immunol 23: 515–48.PubMedGoogle Scholar
  30. Guermonprez, P. and S. Amigorena (2005). “Pathways for antigen cross presentation.” Springer Semin Immunopathol 26(3): 257–71.PubMedGoogle Scholar
  31. Hegde, N. R., M. S. Chevalier, et al. (2003). “Viral inhibition of MHC class II antigen presentation.” Trends Immunol 24(5): 278–85.PubMedGoogle Scholar
  32. Hertel, L., V. G. Lacaille, et al. (2003). “Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus.” J Virol 77(13): 7563–74.PubMedGoogle Scholar
  33. Holtappels, R., V. Bohm, et al. (2008). “CD8 T-cell-based immunotherapy of cytomegalovirus infection: “proof of concept” provided by the murine model.” Med Microbiol Immunol 197(2): 125–34.PubMedGoogle Scholar
  34. Janssen, E. M., E. E. Lemmens, et al. (2003). “CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes.” Nature 421(6925): 852–6.PubMedGoogle Scholar
  35. Jones, T. R. and L. Sun (1997). “Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains.” J Virol 71(4): 2970–9.PubMedGoogle Scholar
  36. Jones, T. R., E. J. Wiertz, et al. (1996). “Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains.” Proc Natl Acad Sci USA 93(21): 11327–33.PubMedGoogle Scholar
  37. Jonjic, S., W. Mutter, et al. (1989). “Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes.” J.Exp.Med. 169: 1199–1212.PubMedGoogle Scholar
  38. Jonjic, S., I. Pavic, et al. (1990). “Efficacious Control of Cytomegalovirus Infection after Long-Term Depletion of CD8+ T Lymphocytes.” J.Virol. 64(11): 5457–64.PubMedGoogle Scholar
  39. Jonjic, S., I. Pavic, et al. (1994). “Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus.” J Exp Med 179(5): 1713–7.PubMedGoogle Scholar
  40. Karrer, U., S. Sierro, et al. (2003). “Memory inflation: continuous accumulation of antiviral CD8+ T cells over time.” J Immunol 170(4): 2022–9.PubMedGoogle Scholar
  41. Kavanagh, D. G., M. C. Gold, et al. (2001). “The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion.” J Exp Med 194(7): 967–78.PubMedGoogle Scholar
  42. Keir, M. E., M. J. Butte, et al. (2008). “PD-1 and its ligands in tolerance and immunity.” Annu Rev Immunol 26: 677–704.PubMedGoogle Scholar
  43. Kessler, T., M. Reich, et al. (2008). “Human cytomegalovirus infection interferes with major ­histocompatibility complex type II maturation and endocytic proteases in dendritic cells at multiple levels.” J Gen Virol 89(Pt 10): 2427–36.PubMedGoogle Scholar
  44. Kielczewska, A., M. Pyzik, et al. (2009). “Ly49P recognition of cytomegalovirus-infected cells expressing H2-Dk and CMV-encoded m04 correlates with the NK cell antiviral response.” J Exp Med 206(3): 515–23.PubMedGoogle Scholar
  45. Kleijnen, M. F., J. B. Huppa, et al. (1997). “A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface.” Embo J 16(4): 685–94.PubMedGoogle Scholar
  46. Kuipers, H., F. Muskens, et al. (2006). “Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.” Eur J Immunol 36(9): 2472–82.PubMedGoogle Scholar
  47. Latchman, Y., C. R. Wood, et al. (2001). “PD-L2 is a second ligand for PD-1 and inhibits T cell activation.” Nat Immunol 2(3): 261–8.PubMedGoogle Scholar
  48. Lee, S. O., S. Hwang, et al. (2005). “Functional dissection of HCMV US11 in mediating the ­degradation of MHC class I molecules.” Biochem Biophys Res Commun 330(4): 1262–7.PubMedGoogle Scholar
  49. Lee, A. W., L. Hertel, et al. (2006). “Human cytomegalovirus alters localization of MHC class II and dendrite morphology in mature Langerhans cells.” J Immunol 177(6): 3960–71.PubMedGoogle Scholar
  50. Lockridge, K. M., S. S. Zhou, et al. (2000). “Primate cytomegaloviruses encode and express an IL-10-like protein.” Virology 268(2): 272–80.PubMedGoogle Scholar
  51. Loewendorf, A., C. Kruger, et al. (2004). “Identification of a mouse cytomegalovirus gene selectively targeting CD86 expression on antigen-presenting cells.” J Virol 78(23): 13062–71.PubMedGoogle Scholar
  52. Lu, X., A. K. Pinto, et al. (2006). “Murine cytomegalovirus interference with antigen presentation contributes to the inability of CD8 T cells to control virus in the salivary gland.” J Virol 80(8): 4200–2.PubMedGoogle Scholar
  53. Lurain, N. S., K. S. Kapell, et al. (1999). “Human cytomegalovirus UL144 open reading frame: sequence hypervariability in low-passage clinical isolates.” J Virol 73(12): 10040–50.PubMedGoogle Scholar
  54. Mathys, S., T. Schroeder, et al. (2003). “Dendritic cells under influence of mouse cytomegalovirus have a physiologic dual role: to initiate and to restrict T cell activation.” J Infect Dis 187(6): 988–99.PubMedGoogle Scholar
  55. McGeoch, D. J., A. Dolan, et al. (2000). “Toward a comprehensive phylogeny for mammalian and avian herpesviruses.” J Virol 74(22): 10401–6.PubMedGoogle Scholar
  56. McGregor, A., F. Liu, et al. (2004). “Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83).” J Virol 78(18): 9872–89.PubMedGoogle Scholar
  57. Mellman, I. (2005). “Antigen processing and presentation by dendritic cells: cell biological mechanisms.” Adv Exp Med Biol 560: 63–7.PubMedGoogle Scholar
  58. Michaelis, M., H. W. Doerr, et al. (2009). “Oncomodulation by human cytomegalovirus: evidence becomes stronger.” Med Microbiol Immunol 198(2): 79–81.PubMedGoogle Scholar
  59. Miller-Kittrell, M. and T. E. Sparer (2009). “Feeling manipulated: cytomegalovirus immune manipulation.” Virol J 6: 4.PubMedGoogle Scholar
  60. Mintern, J. D., E. J. Klemm, et al. (2006). “Viral interference with B7-1 costimulation: a new role for murine cytomegalovirus fc receptor-1.” J Immunol 177(12): 8422–31.PubMedGoogle Scholar
  61. Moutaftsi, M., A. M. Mehl, et al. (2002). “Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells.” Blood 99(8): 2913–21.PubMedGoogle Scholar
  62. Muller, A., L. Schmitt, et al. (1998). “Paralysis of B7 co-stimulation through the effect of viral IL-10 on T cells as a mechanism of local tolerance induction.” Eur J Immunol 28(11): 3488–98.PubMedGoogle Scholar
  63. Munks, M. W., K. S. Cho, et al. (2006). “Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection.” J Immunol 177(1): 450–8.PubMedGoogle Scholar
  64. Munks, M. W., A. K. Pinto, et al. (2007). “Viral interference with antigen presentation does not alter acute or chronic CD8 T cell immunodominance in murine cytomegalovirus infection.” J Immunol 178(11): 7235–41.PubMedGoogle Scholar
  65. Murphy, E., D. Yu, et al. (2003). “Coding potential of laboratory and clinical strains of human cytomegalovirus.” Proc Natl Acad Sci USA 100(25): 14976–81.PubMedGoogle Scholar
  66. Odeberg, J. and C. Soderberg-Naucler (2001). “Reduced expression of HLA class II molecules and Iinterleukin-10- and transforming growth factor beta1-independent suppression of T-cell proliferation in human cytomegalovirus-infected macrophage cultures.” J Virol 75(11): 5174–81.PubMedGoogle Scholar
  67. Pawelec, G., A. Akbar, et al. (2005). “Human immunosenescence: is it infectious?” Immunol Rev 205: 257–68.PubMedGoogle Scholar
  68. Petrovas, C., J. P. Casazza, et al. (2006). “PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection.” J Exp Med 203(10): 2281–92.PubMedGoogle Scholar
  69. Pinto, A. K., M. W. Munks, et al. (2006). “Coordinated function of murine cytomegalovirus genes completely inhibits CTL lysis.” J Immunol 177(5): 3225–34.PubMedGoogle Scholar
  70. Pitcher, C. J., S. I. Hagen, et al. (2002). “Development and homeostasis of T cell memory in rhesus macaque.” J Immunol 168(1): 29–43.PubMedGoogle Scholar
  71. Podlech, J., R. Holtappels, et al. (1998). “Reconstitution of CD8 T cells is essential for the ­prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation.” J Gen Virol 79 ( Pt 9): 2099–104.PubMedGoogle Scholar
  72. Powers, C. and K. Fruh (2008). “Rhesus CMV: an emerging animal model for human CMV.” Med Microbiol Immunol 197(2): 109–15.PubMedGoogle Scholar
  73. Powers, C. J. and K. Fruh (2008). “Signal peptide-dependent inhibition of MHC class I heavy chain translation by rhesus cytomegalovirus.” PLoS Pathog 4(10): e1000150.PubMedGoogle Scholar
  74. Raftery, M. J., M. Schwab, et al. (2001). “Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy.” Immunity 15(6): 997–1009.PubMedGoogle Scholar
  75. Raftery, M. J., D. Wieland, et al. (2004). “Shaping phenotype, function, and survival of dendritic cells by cytomegalovirus-encoded IL-10.” J Immunol 173(5): 3383–91.PubMedGoogle Scholar
  76. Rawlinson, W. D., H. E. Farrell, et al. (1996). “Analysis of the complete DNA sequence of murine cytomegalovirus.” J Virol 70(12): 8833–49.PubMedGoogle Scholar
  77. Reddehase, M. J., F. Weiland, et al. (1985). “Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs.” J Virol 55(2): 264–73.PubMedGoogle Scholar
  78. Rehm, A., A. Engelsberg, et al. (2002). “Human cytomegalovirus gene products US2 and US11 differ in their ability to attack major histocompatibility class I heavy chains in dendritic cells.” J Virol 76(10): 5043–50.PubMedGoogle Scholar
  79. Riddell, S. R. and P. D. Greenberg (1997). “T cell therapy of human CMV and EBV infection in immunocompromised hosts.” Rev Med Virol 7(3): 181–192.PubMedGoogle Scholar
  80. Robbins, S. H., G. Bessou, et al. (2007). “Natural killer cells promote early CD8 T cell responses against cytomegalovirus.” PLoS Pathog 3(8): e123.PubMedGoogle Scholar
  81. Rolle, A. and J. Olweus (2009). “Dendritic cells in cytomegalovirus infection: viral evasion and host countermeasures.” Apmis 117(5–6): 413–26.PubMedGoogle Scholar
  82. Rubin, R. H. (2001). “Cytomegalovirus in solid organ transplantation.” Transpl Infect Dis 3 Suppl 2: 1–5.Google Scholar
  83. Senechal, B., A. M. Boruchov, et al. (2004). “Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83.” Blood 103(11): 4207–15.PubMedGoogle Scholar
  84. Sharpe, A. H. (2009). “Mechanisms of costimulation.” Immunol Rev 229(1): 5–11.PubMedGoogle Scholar
  85. Sierro, S., R. Rothkopf, et al. (2005). “Evolution of diverse antiviral CD8+ T cell populations after murine cytomegalovirus infection.” Eur J Immunol 35(4): 1113–23.PubMedGoogle Scholar
  86. Sinclair, J. (2008). “Human cytomegalovirus: Latency and reactivation in the myeloid lineage.” J Clin Virol 41(3): 180–5.PubMedGoogle Scholar
  87. Sinclair, J. (2008). “Manipulation of dendritic cell functions by human cytomegalovirus.” Expert Rev Mol Med 10: e35.PubMedGoogle Scholar
  88. Slobedman, B., P. A. Barry, et al. (2009). “Virus encoded homologs of cellular interleukin-10 and their control of host immune function.” J Virol 83(19): 9618–29PubMedGoogle Scholar
  89. Snyder, C. M., K. S. Cho, et al. (2008). “Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells.” Immunity 29(4): 650–9.PubMedGoogle Scholar
  90. Snyder, C. M., A. Loewendorf, et al. (2009). “CD4+ T Cell Help Has an Epitope-Dependent Impact on CD8+ T Cell Memory Inflation during Murine Cytomegalovirus Infection.” J Immunol 183(6): 3932–41PubMedGoogle Scholar
  91. Steininger, C., E. Puchhammer-Stockl, et al. (2006). “Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART).” J Clin Virol 37(1): 1–9.PubMedGoogle Scholar
  92. Streblow, D. N., J. Dumortier, et al. (2008). “Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing.” Curr Top Microbiol Immunol 325: 397–415.PubMedGoogle Scholar
  93. Sun, J. C. and M. J. Bevan (2003). “Defective CD8 T cell memory following acute infection without CD4 T cell help.” Science 300(5617): 339–42.PubMedGoogle Scholar
  94. Trombetta, E. S. and I. Mellman (2005). “Cell biology of antigen processing in vitro and in vivo.” Annu Rev Immunol 23: 975–1028.PubMedGoogle Scholar
  95. Tyznik, A. J., E. Tupin, et al. (2008). “Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals.” J Immunol 181(7): 4452–6.PubMedGoogle Scholar
  96. van der Wal, F. J., M. Kikkert, et al. (2002). “The HCMV gene products US2 and US11 target MHC class I molecules for degradation in the cytosol.” Curr Top Microbiol Immunol 269: 37–55.PubMedGoogle Scholar
  97. van Dommelen, S. L., H. A. Tabarias, et al. (2003). “Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells.” J Virol 77(3): 1877–84.PubMedGoogle Scholar
  98. Van Keulen, V. P., B. Ciric, et al. (2006). “Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12.” Clin Exp Immunol 143(2): 314–21.PubMedGoogle Scholar
  99. van Leeuwen, E. M., E. B. Remmerswaal, et al. (2004). “Emergence of a CD4  +  CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection.” J Immunol 173(3): 1834–41.PubMedGoogle Scholar
  100. van Lier, R. A., I. J. ten Berge, et al. (2003). “Human CD8(+) T-cell differentiation in response to viruses.” Nat Rev Immunol 3(12): 931–9.PubMedGoogle Scholar
  101. Varani, S., G. Frascaroli, et al. (2009). “Human cytomegalovirus targets different subsets of ­antigen-presenting cells with pathological consequences for host immunity: implications for immunosuppression, chronic inflammation and autoimmunity.” Rev Med Virol 19(3): 131–45.PubMedGoogle Scholar
  102. Vescovini, R., C. Biasini, et al. (2007). “Massive load of functional effector CD4+ and CD8+ T cells against cytomegalovirus in very old subjects.” J Immunol 179(6): 4283–91.PubMedGoogle Scholar
  103. Vink, C., E. Beuken, et al. (2000). “Complete DNA sequence of the rat cytomegalovirus genome.” J Virol 74(16): 7656–65.PubMedGoogle Scholar
  104. Vyas, J. M., A. G. Van der Veen, et al. (2008). “The known unknowns of antigen processing and presentation.” Nat Rev Immunol 8(8): 607–18.PubMedGoogle Scholar
  105. Walton, S. M., P. Wyrsch, et al. (2008). “The dynamics of mouse cytomegalovirus-specific CD4 T cell responses during acute and latent infection.” J Immunol 181(2): 1128–34.PubMedGoogle Scholar
  106. Walzer, T., M. Dalod, et al. (2005). “Natural killer cell-dendritic cell crosstalk in the initiation of immune responses.” Expert Opin Biol Ther 5 Suppl 1: S49-59.PubMedGoogle Scholar
  107. Wang, S. and L. Chen (2004). “Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses.” Microbes Infect 6(8): 759–66.PubMedGoogle Scholar
  108. Ware, C. F. (2008). “Targeting lymphocyte activation through the lymphotoxin and LIGHT ­pathways.” Immunol Rev 223: 186–201.PubMedGoogle Scholar
  109. Welsh, R. M., J. O. Brubaker, et al. (1991). “Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function.” J Exp Med 173(5): 1053–63.PubMedGoogle Scholar
  110. Wesley, J. D., M. S. Tessmer, et al. (2008). “NK cell-like behavior of Valpha14i NK T cells during MCMV infection.” PLoS Pathog 4(7): e1000106.PubMedGoogle Scholar
  111. Woodland, D. L. and R. W. Dutton (2003). “Heterogeneity of CD4(+) and CD8(+) T cells.” Curr Opin Immunol 15(3): 336–42.PubMedGoogle Scholar
  112. Yewdell, J. W. and A. B. Hill (2002). “Viral interference with antigen presentation.” Nat Immunol 3(11): 1019–25.PubMedGoogle Scholar
  113. Zanghellini, F., S. B. Boppana, et al. (1999). “Asymptomatic primary cytomegalovirus infection: virologic and immunologic features.” J Infect Dis 180(3): 702–7.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2012

Authors and Affiliations

  1. 1.Division of Immune RegulationLa Jolla Institute for Allergy and ImmunologyLa JollaUSA
  2. 2.Division of Developmental ImmunologyLa Jolla Institute for Allergy and ImmunologyLa JollaUSA
  3. 3.Division of Molecular ImmunologyLa Jolla Institute for Allergy and ImmunologyLa JollaUSA
  4. 4.Division of Molecular Immunology, Cincinnati Children’s Hospital Research FoundationUniversity of Cincinnati College of MedicineCincinnatiUSA

Personalised recommendations